ACTU: Kapitalisasi marang pendapatan Actuate Therapeutics Inc

Simbol lan logo merek Actuate Therapeutics Inc (ACTU)

Actuate Therapeutics, Inc. (ACTU) bases its efficiency on strict control of biosample transportation to ensure data accuracy. The development of therapies for melanoma, leukemia, and pancreatic cancer reduces approval risks, which is confirmed by the current price-to-sales ratio; the value of reflects this status. The company's prospects are further enhanced by the implementation of automated manipulators in laboratories to accelerate early-phase research validation.

ACTU - Kapitalisasi marang pendapatan Actuate Therapeutics, Inc. ing rentang 04.07.2022 - 16.11.2026

Actuate Therapeutics, Inc (ACTU) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Analisis umum perusahaan:ACTU - Actuate Therapeutics, Inc
Produk mawa merek Actuate Therapeutics Inc.

The P/S ratio determines the investment attractiveness of Actuate Therapeutics, Inc. (ACTU) by comparing market capitalization with annual sales volume to identify whether the asset is overvalued relative to actual cash flows. By analyzing the P/S chart, an investor can gauge the level of venture risk within the non-cyclical nature of cancer treatment biotechnology, where demand is driven by medical necessity, ensuring high operational resilience of the business against macroeconomic shocks.

Karo sapa Actuate Therapeutics, Inc. saingan

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|Citius Oncology (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd